Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Icotinib
  • 1.4.3 Gefitinib
  • 1.4.4 Erlotinib
  • 1.4.5 Afatinib
  • 1.4.6 Osimertinib
  • 1.4.7 Brigatinib
  • 1.4.8 Other
• 1.5 Market by Application
  • 1.5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2014-2025)
  • 1.5.2 Squamous Cell Carcinoma of NSCLC
  • 1.5.3 Adenocarcinoma of NSCLC
  • 1.5.4 Large Cell Carcinoma of NSCLC
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size
• 2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Regions
  • 2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (2014-2025)
  • 2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by by Players
  • 3.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by by Players (2014-2019)
  • 3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
• 3.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served
• 3.3 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product/Solution/Service
• 3.4 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2014-2019)
• 4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2014-2019)

5 United States

• 5.1 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
• 5.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in United States
• 5.3 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
• 5.4 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

6 Europe

• 6.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
• 6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Europe
• 6.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
• 6.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

7 China

• 7.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
• 7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in China
• 7.3 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
• 7.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

8 Japan

• 8.1 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
• 8.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Japan
• 8.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
• 8.4 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
• 9.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Southeast Asia
• 9.3 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
• 9.4 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

10 India

• 10.1 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
• 10.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in India
• 10.3 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
• 10.4 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

11 Central & South America

• 11.1 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
• 11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Central & South America
• 11.3 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
• 11.4 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

12 International Players Profiles

• 12.1 Beta Pharma
  • 12.1.1 Beta Pharma Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.1.5 Beta Pharma Recent Development
• 12.2 AstraZeneca
  • 12.2.1 AstraZeneca Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.2.5 AstraZeneca Recent Development
• 12.3 Natco Pharma
  • 12.3.1 Natco Pharma Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.3.5 Natco Pharma Recent Development
• 12.4 Qilu Pharmaceutical
  • 12.4.1 Qilu Pharmaceutical Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.4.5 Qilu Pharmaceutical Recent Development
• 12.5 Genentech (Roche Group)
  • 12.5.1 Genentech (Roche Group) Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.5.5 Genentech (Roche Group) Recent Development
• 12.6 Mylan
  • 12.6.1 Mylan Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.6.5 Mylan Recent Development
• 12.7 Teva
  • 12.7.1 Teva Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.7.5 Teva Recent Development
• 12.8 OSI Pharmaceuticals
  • 12.8.1 OSI Pharmaceuticals Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.8.5 OSI Pharmaceuticals Recent Development
• 12.9 Glenmark Pharmaceuticals
  • 12.9.1 Glenmark Pharmaceuticals Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.9.5 Glenmark Pharmaceuticals Recent Development
• 12.10 Beacon Pharmaceuticals
  • 12.10.1 Beacon Pharmaceuticals Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
  • 12.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
  • 12.10.5 Beacon Pharmaceuticals Recent Development
• 12.11 Boehringer Ingelheim
• 12.12 Pfizer
• 12.13 ARIAD Pharmaceuticals (Takeda)
• 12.14 Genvio Pharma Limited
• 12.15 Drug International Limted
• 12.16 Everest Pharmaceuticals
• 12.17 Incepta Pharmaceuticals Limited
• 12.18 Cipla Pharma
• 12.19 Dr Reddy's Laboratories
• 12.20 Zydus Cadila
• 12.21 Hetero Drugs
• 12.22 Intas Pharmaceuticals
• 12.23 Alkem Laboratories
• 12.24 RPG Life Sciences
• 12.25 Fresenius Kabi India

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer